ARCHIVES

FDA Asks Advisory Group To Define Role Of Single-Arm Studies In Four Applications

This article is from The Cancer Letter archive.

Vol. 35 No. 32 | September 4, 2009

Download PDF Visit The Full Archive

Related Articles

Amgen Halts Phase III Trial Of Ganitumab Plus Gemcitabine

August 31, 2012

Matrisian, Nelson, to lead review of NCI translational research programs.

September 23, 2005

Professional Societies: Three Groups To File brief In Fisher’s Appeal

October 11, 1996

It’s Official; Most of NCI NTP contingent Will Move To N.C.

February 22, 1980

NCI Pulls Back Curtain on “Zone of Uncertainty” — Funding Patterns Released With Little Comment

May 4, 2012

Phase III Custirsen/Docetaxel/Prednisone Trial Fails Primary Endpoint of Overall Survival

April 25, 2014